Capital Fund Management (CFM)
ESPR

Capital Fund Management (CFM)’s Esperion Therapeutics ESPR Stock Holding History

Capital Fund Management (CFM)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-31,597
Closed -$1.62M – 1260
2020
Q2 		$1.62M Buy
+31,597
New +$1.32M 0.03% 564
2020
Q1 		– Sell
-10,250
Closed -$611K – 1687
2019
Q4 		$611K Buy
+10,250
New +$461K ﹤0.01% 1302
2015
Q4 		– Sell
-9,280
Closed -$219K – 1601
2015
Q3 		$219K Buy
+9,280
New +$582K ﹤0.01% 1304

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capital Fund Management (CFM)'s ESPR Position: Q3 2020 in Review

Capital Fund Management (CFM) sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 31,597 shares — an estimated $1.62M sold.

Capital Fund Management (CFM) first reported a position in ESPR in Q3 2015 and held it in 3 quarters. The position peaked at $1.62M in Q2 2020. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • Capital Fund Management (CFM) reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 31,597 Esperion Therapeutics shares in Q3 2020, an estimated $1.62M.
  • Capital Fund Management (CFM) first reported a position in Esperion Therapeutics in Q3 2015 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Esperion Therapeutics position peaked at $1.62M in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2020, filed 13 Nov 2020.